Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(0.70%) (38.64%) (39.90%) (38.71%)

+8 more TTM periods

Piotroski F-Score
5 5 5 5
ROA
(0.20%) (13.00%) (13.52%) (12.85%)
ROIC
1.58% (11.20%) (11.87%) (11.73%)
Return on Tangible Assets
(0.55%) (38.98%) (44.99%) (40.70%)
Average Days of Receivables
59.19 58.69 62.24 58.24
Free Cash Flow per Share
0.33 0.05 (0.40) (0.06)
Free Cash Flow
25.80 4.08 (31.05) (4.51)
Capital Expenditures
(59.52) (67.36) (81.44) (93.82)
Other line items
Cash ROIC
0.82% 0.13% (0.99%) (0.15%)
Accounts Receivable Turnover
5.97 6.36 5.93 6.44
Accounts Payable Turnover
8.93 8.82 9.02 9.22
Inventory Turnover
1.64 1.68 1.74 1.69
Average Days of Payables
38.52 40.62 43.48 43.02
Days of Inventory on Hand
229.33 228.62 223.80 227.96
Tax Rate
39.46 (0.07) (0.08) (0.09)
Research and Development Expense of Revenue
5.77% 5.94% 6.05% 6.41%
Selling, General and Administrative Expense of Revenue
41.82% 42.35% 42.79% 43.15%
Share Based Compensation of Revenue
1.36% 1.33% 1.14% 1.21%
Interest Coverage
0.71 (5.19) (5.72) (5.89)
Operating CF/Net income
(11.78) (0.14) (0.10) (0.18)
Depreciation/Fixed assets
0.35 0.35 0.35 0.36
Capex/Depreciation
(0.38) (0.43) (0.52) (0.60)
Revenue per Share
21.32 21.37 21.33 21.41
Operating CF per Share
1.10 0.93 0.66 1.16
Capex per Share
(0.77) (0.88) (1.06) (1.22)
Capex to Sales
0.04 0.04 0.05 0.06

Fold the line items

Columns are period end dates